tiprankstipranks
Trending News
More News >
Noxopharm Ltd. (AU:NOX)
ASX:NOX
Australian Market
Advertisement

Noxopharm Ltd. (NOX) Drug Pipeline

Compare
3 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Sof-Skn 0.25%, Sof-Skn 0.5%, Sof-Skn 1%, Sof-Skn 2%
Cutaneous Lupus Erythematosus
Early Phase I
Recruiting
Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants
Jun 16, 2025
Doxorubicin, Nox66
Metastatic Soft-Tissue Sarcoma
Phase I
Terminated
A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma
Oct 20, 2021
Nox66, Irradiation Therapy
Cancer
Phase I
Completed
Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer
Sep 27, 2017

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does Noxopharm Ltd. (NOX) have in its pipeline
      NOX is currently developing the following drugs: Sof-Skn 0.25%, Sof-Skn 0.5%, Sof-Skn 1%, Sof-Skn 2%, Doxorubicin, Nox66, Nox66, Irradiation Therapy. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis